Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection
- PMID: 12479825
- DOI: 10.1016/s1074-7613(02)00482-x
Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection
Abstract
Long-term display of exogenous proteins on the cell surface may have important research and therapeutic implications. We report a novel method for the cell-surface display of proteins that involves generation of a chimeric protein with core streptavidin, biotinylation of cells, and "decoration" with the protein. A chimeric protein with the extracellular portions of FasL (SA-FasL) was efficiently displayed on the cell surface within 2 hr without detectable cellular toxicity. Biotin and SA-FasL persisted on the cell surface for weeks in vitro and in vivo. Immunomodulation with SA-FasL-decorated splenocytes effectively blocked alloreactive responses in naive and presensitized rodents and prevented the rejection of allogeneic pancreatic islets. This approach may serve as an alternative to gene transfer-based expression with broad research and therapeutic applications.
Similar articles
-
Immunomodulation with SA-FasL protein as an effective means of preventing islet allograft rejection in chemically diabetic NOD mice.Transplant Proc. 2013 Jun;45(5):1889-91. doi: 10.1016/j.transproceed.2013.01.041. Transplant Proc. 2013. PMID: 23769064 Free PMC article.
-
Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection.Circulation. 2003 Mar 25;107(11):1525-31. doi: 10.1161/01.cir.0000064893.96179.7e. Circulation. 2003. PMID: 12654611
-
ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.Ann N Y Acad Sci. 2005 Nov;1056:344-58. doi: 10.1196/annals.1352.036. Ann N Y Acad Sci. 2005. PMID: 16387700
-
Localized immune tolerance from FasL-functionalized PLG scaffolds.Biomaterials. 2019 Feb;192:271-281. doi: 10.1016/j.biomaterials.2018.11.015. Epub 2018 Nov 13. Biomaterials. 2019. PMID: 30458362 Free PMC article.
-
Fas Ligand-Modified Scaffolds Protect Stem Cell Derived β-Cells by Modulating Immune Cell Numbers and Polarization.ACS Appl Mater Interfaces. 2022 Dec 19. doi: 10.1021/acsami.2c12939. Online ahead of print. ACS Appl Mater Interfaces. 2022. PMID: 36533683 Review.
Cited by
-
Immunomodulation with SA-FasL protein as an effective means of preventing islet allograft rejection in chemically diabetic NOD mice.Transplant Proc. 2013 Jun;45(5):1889-91. doi: 10.1016/j.transproceed.2013.01.041. Transplant Proc. 2013. PMID: 23769064 Free PMC article.
-
Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.J Diabetes Sci Technol. 2008 Sep;2(5):746-59. doi: 10.1177/193229680800200502. J Diabetes Sci Technol. 2008. PMID: 19885257 Free PMC article.
-
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.Blood. 2008 Apr 1;111(7):3546-52. doi: 10.1182/blood-2007-09-113522. Epub 2007 Dec 20. Blood. 2008. PMID: 18096763 Free PMC article.
-
Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.Blood Adv. 2023 May 23;7(10):2181-2195. doi: 10.1182/bloodadvances.2022008495. Blood Adv. 2023. PMID: 36780582 Free PMC article.
-
A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo.Oncotarget. 2016 Mar 15;7(11):12176-90. doi: 10.18632/oncotarget.7519. Oncotarget. 2016. PMID: 26910923 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
